Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes

Cytometry Part B - Clinical Cytometry

Volumn 84 B, Issue 3, 2013, Pages 157-166

  Sandes, Alex F ^a   Kerbauy, Daniella M B ^a   Matarraz, Sergio ^b   Chauffaille, Maria De Lourdes L F ^a   Lõpez, Antonio ^b   Orfao, Alberto ^b   Yamamoto, Mihoko ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

blast cell count; flow cytometry; morphology; myelodysplastic syndromes

Indexed keywords

CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD64 ANTIGEN; HLA DR ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLAST CELL; CELL COUNT; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, CD45; BIOLOGICAL MARKERS; CELL COUNT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE PRECURSOR CELLS; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS C-KIT; REPRODUCIBILITY OF RESULTS;

EID: 84876487323     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21087     Document Type: Article

References (33)

1. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Vollmer RT,. Blast counts in bone marrow aspirate smears: analysis using the poisson probability function, bayes theorem, and information theory. Am J Clin Pathol 2009; 131: 183-188.
4. List AF, Vardiman J, Issa JP, DeWitte TM,. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2004: 297-317.
5. Vardiman JW,. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2006: 199-204.
6. Jelic TM, Mellen PF, Zavieh K, Roque JC, Farren SP, Jin B, Ahmad N, Estallila OC, Chang HH,. Correlation between the percentages of myeloblasts in bone marrow obtained by flow cytometry and manual counting on glass slide smears in 74 hematologic patients. Leuk Lymphoma 2002; 43: 1927-1931.
7. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ,. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
8. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA,. Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 2008; 32: 5-17.
9. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, et al. Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124-1134.
10. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A,. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 1037-1044.
11. Ogata K,. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 2008; 26: 193-198.
12. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, et al. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730-1741.
13. Brunning RD, Orazi A, Germing U, LeBeau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E,. Myelodysplastic syndromes/neoplasms, overview. In:, Swerdlow SH, Campo EH NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 88-93.
14. Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC,. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 2008; 30: 349-364.
15. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, Cazzola M, Fenaux P, Germing U, Hellstrom-Lindberg E, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008; 93: 1712-1717.
16. Stewart CC, Stewart SJ,. Immunophenotyping. Curr Protoc Cytom 2001;Chapter 6:Unit 62.
17. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I,. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
18. Garcia-Manero G,. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 490-498.
19. Ramos F, Fernandez-Ferrero S, Suarez D, Barbon M, Rodriguez JA, Gil S, Megido M, Ciudad J, Lopez N, del Canizo C, et al. Myelodysplastic syndrome: A search for minimal diagnostic criteria. Leuk Res 1999; 23: 283-290.
20. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ,. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067-1077.
21. Craig FE, Foon KA,. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-3967.
22. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA,. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 2009; 76B: 27-36.
23. van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ,. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004; 60B: 1-13.
24. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME,. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
25. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J, Barcena P, Rasillo A, Sayagues JM, Sanchez ML, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175-1183.
26. Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J,. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004; 58A: 62-71.
27. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sanchez ML, Barcena P, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry B Clin Cytom 2010; 78B: 154-168.
28. Bjornsson S, Wahlstrom S, Norstrom E, Bernevi I, O'Neill U, Johansson E, Runstrom H, Simonsson P,. Total nucleated cell differential for blood and bone marrow using a single tube in a five-color flow cytometer. Cytometry B Clin Cytom 2008; 74: 91-103.
29. Allan RW, Ansari-Lari MA, Jordan S,. DRAQ5-based, no-lyse, no-wash bone marrow aspirate evaluation by flow cytometry. Am J Clin Pathol 2008; 129: 706-713.
30. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ,. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112: 2681-2686.
31. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, Woda BA, Wang SA,. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-224.
32. Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Lowenberg B, Gratama JW,. Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination. Cytometry B Clin Cytom 2009; 76B: 18-26.
33. Holdrinet RS, von Egmond J, Wessels JM, Haanen C,. A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol 1980; 8: 103-107.